Just Released: "Lupus Nephritis - Pipeline Review, H2 2013"

From: Fast Market Research, Inc.
Published: Fri Nov 01 2013


Global Markets Direct's, 'Lupus Nephritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lupus Nephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lupus Nephritis. Lupus Nephritis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Lupus Nephritis.
* A review of the Lupus Nephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Lupus Nephritis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Full Report Details at
- http://www.fastmr.com/prod/689138_lupus_nephritis_pipeline_review_h2_2013.aspx?afid=303

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Bristol-Myers Squibb Company, Baxter International Inc., Johnson & Johnson, Biogen Idec Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, NOXXON Pharma AG

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Systemic Lupus Erythematosus - Pipeline Review, H2 2013
- Lupus Nephritis - Pipeline Review, H1 2013
- Lupus Erythematosus - Pipeline Review, H2 2013
- Lupus Nephritis Global Clinical Trials Review, H1, 2013
- Alzheimer's Disease - Pipeline Review, H2 2013
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »